Established in 1998, Zhejiang Haisen Pharmaceutical Co., Ltd. (Zhejiang Haisen) is a medium-scale enterprise which is mainly engaged in the R&D, production and operation of API and pharmaceutical intermediates. It is a state hi-tech enterprise, covering an area of 70,000 ㎡ with fixed asset of USD37.52 million (RMB 230 million) and over 450 employees including 32% professional technicians. Zhejiang Haisen has gained the certifications of ISO9001 Quality Management System, ISO14001 Environment Management System, GMP (Good Manufacture Practice), EU-CEP (Certification of Suitability to Monograph of European Pharmacopeia), COFEPRIS (the Federal Health Risk Prevention Committee Affiliated by the Mexico Ministry of Health) certificate, and US-FDA (the US Food and Drug Administration) approved.
It has built a long term good cooperation relationship with research institutes, such as Sichuan Industrial Institute of Antibiotics, Shanghai Institute of Pharmaceutical Industry and Tianjin Institute of Pharmaceutical Research.
The main products are API: metamizole sodium (analgin); pazufloxacin mesilate, paroxetine hydrochloride, granisetron hydrochloride, sucralfate, escitalopram oxalate; atovastatin calium; l-glutamine; intermediates: PHBA, n-methyl paroxetine, trans-paroxol and so on.
